Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company experienced a revenue decline of 11.1% year-on-year in the first half of the year, with total revenue reaching 500 million yuan. The net profit attributable to shareholders was 40 million yuan, down 20.1% year-on-year. In Q2, revenue was 223 million yuan, a decrease of 24.2%, and the net profit was 440,000 yuan, down 98.3% year-on-year [2][4]. Financial Performance - The company's revenue from the pharmaceutical glass segment was 203 million yuan, down 20.47% year-on-year, attributed to weak pharmaceutical demand and the impact of centralized procurement. The revenue from the heat-resistant glass segment remained stable at 284 million yuan, with a slight decline of 0.28% [9]. - The gross profit margin for the first half of 2025 was 21.5%, an increase of 1.2 percentage points year-on-year, mainly due to improved margins in the heat-resistant glass segment. The gross margin for pharmaceutical glass was 19.95%, down 4.15 percentage points, while the heat-resistant glass margin was 22.34%, up 5.18 percentage points [9]. - The company’s expense ratio for the first half of 2025 was 14.5%, an increase of 3.8 percentage points, with management, sales, financial, and R&D expense ratios rising by 1.2, 1.4, 0.6, and 0.5 percentage points respectively [9]. Strategic Developments - The company is advancing its mergers and acquisitions, having signed a share transfer agreement with Shanghai Miaoxiang, planning to acquire 34.05 million shares of Suzhou Chuangyang New Materials Technology Co., Ltd. for a total consideration of 84 million yuan. Post-acquisition, the company will hold 30% of the target company, which specializes in pharmaceutical plastic combination caps [9]. - The company is transitioning from controlled to molded glass production, with expectations for increased output of its borosilicate molded bottles. The company’s borosilicate molded injection bottles have passed regulatory approval, and further client registrations are anticipated to lead to a volume increase [9]. Market Outlook - The pharmaceutical glass market in China was valued at 28.6 billion yuan in 2021, growing by 11.7% year-on-year, and is projected to reach 35 billion yuan in 2023, with an expected CAGR of 8.51% from 2023 to 2026 [9]. - The company’s projected net profits for 2025 and 2026 are 110 million yuan and 170 million yuan respectively, corresponding to PE ratios of 44 and 28 times [9].

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Views - The report indicates that the company has ended its pressure testing phase and is looking forward to a simultaneous increase in both volume and price [6]. - In the first half of 2025, the company achieved revenue of 10.55 billion yuan, a year-on-year increase of 2.17%, while the net profit attributable to shareholders was 288 million yuan, a year-on-year decline of 32.69% [2][6]. - The company has shown resilience in production, with a total output of 2.363 million tons in the first half of 2025, representing a year-on-year growth of 12.2% [12]. Financial Performance - The company reported a net profit of 288 million yuan in the first half of 2025, with a non-recurring net profit of 238 million yuan, which is a year-on-year increase of 0.88% [2][6]. - The second quarter of 2025 saw a decrease in gross profit per ton to 465 yuan, primarily due to falling steel prices [12]. - The operating cash flow for the second quarter improved year-on-year, with a net outflow of 3 million yuan, which is a reduction of 12.7 million yuan compared to the previous year [12]. Market Position and Strategy - The company has been actively adjusting its sales strategies, resulting in a year-on-year increase in orders [12]. - The report highlights the potential for price recovery in the cyclical products market, which could positively impact the company's profitability [12]. - The company is focusing on increasing the application of welding robots, which is expected to enhance efficiency and reduce costs in the future [12]. Future Outlook - The report suggests that the current low steel prices provide a safety margin, with expectations for profit release in the coming year [12]. - The company is positioned as a leading player in the cyclical market, with high potential for growth as market conditions improve [12].

2025 年 08 月 25 日 利润显著修复，终端开瓶向好 买入(维持) 事件 | 分析师：孙山山 | S1050521110005 | | --- | --- | | sunss@cfsc.com.cn | | | 联系人：张倩 | S1050124070037 | | zhangqian@cfsc.com.cn | | | 基本数据 | 2025-08-22 | | --- | --- | | 当前股价（元） | 60.91 | | 总市值（亿元） | 203 | | 总股本（百万股） | 333 | | 流通股本（百万股） | 333 | | 52 周价格范围（元） | 40.18-82.9 | | 日均成交额（百万元） | 637.75 | 市场表现 -20 0 20 40 60 80 100 (%) 舍得酒业 沪深300 资料来源：Wind，华鑫证券研究 相关研究 1、《舍得酒业（600702）：业绩表 现承压，期待弹性恢复》2025-05- 07 2、《舍得酒业（600702）：业绩短 期承压，期待企稳回升》2025-03- 24 3、《舍得酒业（600702）：调整期 业绩承压，发布回购方案彰 ...

研究所： 证券分析师： 年庆功 S0350524060001 nianqg@ghzq.com.cn [Table_Title] 2025 年 Q2 利润同比回升，研发投入不断加强 最近一年走势 事件: 2025 年 8 月 22 日安图生物发布 2025 年半年度报告：2025 年上半年 公司营业收入 20.60 亿元（yoy-6.65%），归母净利润 5.71 亿元 （yoy-7.83%），扣非归母净利润 5.46 亿元（yoy-8.79%)。 投资要点: 2025 年 08 月 25 日 公司研究 评级：买入(维持) ——安图生物（603658）2025 年半年报点评 2025 年 Q2 归母净利润同比增长。 2025 年上半年公司营业收入 20.60 亿元（yoy-6.65%），归母净利润 5.71 亿元（yoy-7.83%）， 扣非归母净利润 5.46 亿元（yoy-8.79%)。2025 年 Q2 公司营业收入 10.64 亿元（yoy-4.79%），归母净利润 3.01 亿元（yoy+1.97%）， 扣非母净利润 2.89 亿元（yoy+1.58%）。 2025年Q2净利润率同比提升。 2025年 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company achieved a record high revenue of 2.9 billion yuan in Q2 2025, doubling both year-on-year and quarter-on-quarter [1][5] - The company has successfully expanded its product lines to include mobile storage, solid-state drives (SSDs), embedded storage, and memory modules, with significant revenue growth in 2024 [5] - The company has established a strong client base across various industries, including cloud service providers and AIoT terminal manufacturers [5] Financial Data and Profit Forecast - Total revenue projections are as follows: 2024: 4,773 million yuan, 2025H1: 4,109 million yuan, 2025E: 8,325 million yuan, 2026E: 9,326 million yuan, 2027E: 11,327 million yuan [4] - Year-on-year growth rates for revenue are projected at 168.7% for 2024, 88.8% for 2025H1, and 74.4% for 2025E [4] - The net profit attributable to the parent company is forecasted to be 351 million yuan in 2024, 725 million yuan in 2025E, 845 million yuan in 2026E, and 1,046 million yuan in 2027E [4] - The company’s gross margin is expected to improve from 5.0% in 2025H1 to 16.4% in 2026E [4] - The company’s return on equity (ROE) is projected to be 22.5% in 2025E, 20.8% in 2026E, and 20.5% in 2027E [4] Market Data - As of August 25, 2025, the closing price is 99.61 yuan, with a market capitalization of 15,915 million yuan [2] - The price-to-earnings (PE) ratio is estimated at 31 for 2025 [4]

上 市 公 司 建筑装饰 2025 年 08 月 25 日 中钢国际 (000928) ——工程毛利率改善，境外业务收入逆势提升 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 08 月 25 日 | | --- | --- | | 收盘价（元） | 6.71 | | 一年内最高/最低（元） | 7.76/5.15 | | 市净率 | 1.1 | | 股息率%（分红/股价） | 4.46 | | 流通 A 股市值（百万元） | 9,626 | | 上证指数/深证成指 | 3,883.56/12,441.07 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 5.80 | | 资产负债率% | 66.65 | | 总股本/流通 A 股（百万） | 1,435/1,435 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 08-26 09-26 10-26 11-26 12-26 01-26 02-26 03-26 04-26 05-2 ...

上 市 公 司 房地产 2025 年 08 月 25 日 保利发展 (600048) ——业绩下滑符合预期，拿地修复、融资成本创新低 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 08 月 25 日 | | --- | --- | | 收盘价（元） | 8.30 | | 一年内最高/最低（元） | 12.13/7.30 | | 市净率 | 0.5 | | 股息率%（分红/股价） | 2.05 | | 流通 A 股市值（百万元） | 99,355 | | 上证指数/深证成指 | 3,883.56/12,441.07 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 16.18 | | 资产负债率% | 73.53 | | 总股本/流通 A 股（百万） | 11,970/11,970 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 08-26 09-26 10-26 11-26 12-26 01-26 02-26 03-26 04- ...

丨证券研究报告丨 公司研究丨点评报告丨福耀玻璃（600660.SH） [Table_Title] 福耀玻璃中报点评：规模效应叠加量价齐升，业 绩表现超预期，首次中期分红 报告要点 [Table_Summary] 公司高附加值产品渗透率持续增长加之全球市占率持续提升，公司 2025Q2 实现营业收入115.4 亿元，同比+21.4%；归母净利润 27.7 亿元，同比+31.5%。规模效应叠加纯碱等原材料成本下 降，公司盈利水平表现优异。展望未来，福耀作为最专注的全球汽车玻璃龙头，护城河将不断 变宽，公司中长期投资价值凸显。 分析师及联系人 [Table_Author] 高伊楠 王子豪 SAC：S0490517060001 SAC：S0490524070004 SFC：BUW101 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 福耀玻璃（600660.SH） cjzqdt11111 [Table_Title 福耀玻璃中报点评：规模效应叠加量价齐升，业 2] 绩表现超预期，首次中期分红 [Table_Summary2] 事件描述 公司 2025Q2 实现营业收入 1 ...

中航沈飞（600760.SH） 2025 年 08 月 25 日 买入（维持评级） 公司点评 证券研究报告 25Q2 业绩环比高增，新产能建设彰显 发展信心 业绩简评 公司发布 2025 半年报，25H1 实现营收 146.28 亿（-32.4%），归母 净利润 11.36 亿（-29.8%）；25Q2 实现营收 87.95 亿，同比-27.5%， 环比+50.8%；实现归母净利润 7.06 亿，同比-21.8%，环比+63.9%。 经营分析 25Q2 公司业绩环比大幅增长或已实现筑底，合同负债大幅增加反 映订单修复：25Q2 公司实现营收 87.95 亿（-27.5%），环比+50.8%， 归母净利润 7.06 亿（-21.8%），环比+63.9%，业绩同比下滑主要 受产品配套交付进度及产品结构调整所致。截至 25Q2 季度末，公 司合同负债为 75.32 亿，较 24 年末增加 113.47%，主要系收到预 收款增加所致,反映订单端得到修复。 毛利率维持平稳，归母净利率小幅提升：1）25H1公司毛利率12.3%， 同比-0.3pct 维持稳定，归母净利率 7.8%，同比+0.3pct；25Q2 公司毛利率 ...

Investment Rating - The report maintains a "Buy" rating for Wanhua Chemical [1][7][17] Core Views - The company's Q2 performance shows signs of stabilization, with expectations for a cyclical recovery in the industry [5][11] - In H1 2025, the company achieved total revenue of 90.901 billion yuan, a year-on-year decrease of 6.35%, and a net profit attributable to shareholders of 6.123 billion yuan, down 25.10% year-on-year [4][5] - The polyurethane sector is expected to improve profitability due to rising TDI and MDI prices, while the petrochemical segment faces challenges from oversupply [5][6] Summary by Sections Financial Performance - In Q2 2025, the company reported revenue of 47.833 billion yuan, an 11% increase quarter-on-quarter, with net profit of 3.04 billion yuan remaining stable [5] - The company’s second ethylene unit with a capacity of 1.2 million tons/year has successfully commenced operations [6] Business Segments - The polyurethane industry shows stable demand, particularly in the new energy and high-end manufacturing sectors, driven by the lightweight requirements of electric vehicles [5] - The fine chemicals and new materials segments are experiencing steady growth, with ongoing product and capacity releases contributing to revenue stability [5][6] Future Outlook - The company is expected to see EPS of 4.3, 5.34, and 6.29 yuan for 2025, 2026, and 2027 respectively, indicating a positive growth trajectory [7][8] - The report anticipates a revenue growth rate of 10.91% in 2025, with further increases in subsequent years [8][13]